Harvest One Cannabis Inc. announces Renewal of License and Submission of ACMPR Sales Amendment Application; Execution of Wholesale Off-take Agreement
Harvest One Cannabis Inc.(TSXV:HVST) through its wholly owned subsidiary United Greeneries Ltd. (“UG“) is pleased to announce that UG has received a renewal of its its Access to Cannabis for Medical Purposes Regulations (“ACMPR“) cultivation license (the “License“), and it has submitted an application to Health Canada to amend its License to allow for the sale and distribution of medical cannabis (the “Amendment“).
Renewal of License
UG is pleased to announce that it has received the renewal of its License. The License is valid until June 26, 2020. Health Canada has removed the previous production and storage capacity of the License. UG is now permitted to store up to $6,250,000 worth of cannabis at any given time in its Level 8 vault.
The application for the Amendment follows the harvest of two independent consecutive cannabis crops and the successful completion of certain biochemical quality control standards and analytical requirements. The issuance of the Amendment is subject to, among other things, a regulatory inspection of UG’s growing facility in Duncan, BC (the “Duncan Facility“) and cannot be guaranteed by the Company. However, the Company is confident that UG is compliant with all necessary requirements, that the Duncan Facility will pass the required inspection and that the Amendment will be issued in due course.
Agreement with another Licensed Producer (“LP“)
In addition, UG is pleased announce that it has entered into a wholesale off-take agreement (the “Wholesale Agreement“) with another LP for the sale of its initial 100kg of cannabis production for a fixed price of CAD$500,000 (or $5 per gram), subject to the receipt of the Amendment. The Wholesale Agreement also includes a right of first refusal for the LP to wholesale purchase UG’s further production for a period of 12 months.
Subject to the receipt of the Amendment, UG plans to continue wholesale distribution and to closely collaborate with this LP in the medical cannabis market while the Company builds a retail platform for the recreational cannabis market over the next few months.
Andreas Gedeon, Managing Director and CEO, comments: “I am delighted to report that our operational activities are unfolding according to our business plan and that our strategic efforts to build a leading international cannabis company are coming together. The issuing of the sales and distribution Amendment to United Greeneries’ cultivation license under the ACMPR will constitute a significant value catalyst for our shareholders. We will be providing the market with further operational updates and a strategic outlook for the months ahead shortly.”
About Harvest One
Harvest One Cannabis Inc. (TSXV:HVST) controls operations across the entire cannabis value chain through three business units, with Harvest One serving as the umbrella company over horticultural arm United Greeneries and medical arm Satipharm AG. Each business is strategically located in favourable jurisdictions with supportive regulatory frameworks in place. United Greeneries has received a Canadian medicinal cannabis cultivation license, making Harvest One one of only a few companies globally with the capacity to commercially cultivate cannabis in a federally regulated environment.
Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the application for the Amendment and the expansion of the Duncan Facility. The Amendment and expansion of the Duncan Facility, respectively, are subject to applicable regulatory approvals, and there can be no assurance that such approvals will be received in the timeframe contemplated in this press release or at all. The business of the Company is subject to a number of material risks and uncertainties. Please refer to the Company’s SEDAR filings for further details. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.
Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.
The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).